Drugs Made In America Acquisition II Corp.
corporate_fare Company Profile
Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) is a publicly traded company in the Industrials sector. Wiseek monitors DMII SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- SPAC DMII Posts $4.34M Net Income in Q1 2026, Reversing Prior Loss
- Company Discloses Material Weakness in Internal Controls, Reaffirms Going Concern
- DMII Formalizes CEO & CFO Compensation with Significant Equity Grants Amid Cash Flow Constraints
- SPAC Discloses Going Concern, Sponsor Default, CEO Ousting, and Material Weaknesses
- DMII Secures $1.4M Financing with 35% Discount Convertible Notes for De-SPAC, Addresses Sponsor Transition
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for DMII, detected from its recent SEC filings · based on capital-structure filings through 2026-03-17.
Bridge Loan Secured · Planned Larger Financing
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →